<DOC>
	<DOCNO>NCT01303965</DOCNO>
	<brief_summary>One complication occur stem cell transplant call graft versus host disease ( GVHD ) . Another complication multiple myeloma may come back ( relapse ) . In study , drug call lenalidomide start 1-2 month transplant , possibly later depend recovery side effect . Lenalidomide sirolimus show work together multiple myeloma . Therefore , lenalidomide combine sirolimus hope help prolong amount time disease remission . Researchers hope step help prolong amount time multiple myeloma remission decrease chance GvHD .</brief_summary>
	<brief_title>Allo Transplant Followed Lenalidomide Sirolimus Maintenance High-Risk Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Recipient 1 . Understand voluntarily sign informed consent form . 2 . Age 1870 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Previously document multiple myeloma ( MM ) measurable monoclonal protein either serum/urine protein electrophoresis serum free light chain , measurable plasmacytoma . 5 . ECOG performance status 02 study entry ( see Appendix 2 ) . 6 . Acceptable organ function outline protocol . 7 . Otherwise fitting institutional criterion allogeneic stem cell transplantation . 8 . Presence HLAmatched ( 5/6 6/6 match HLAA , B , DR ) sibling donor , HLAmatched ( match least HLAA , B , C , DRB1 ) unrelated donor highresolution test . 9 . Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 10 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . 11 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test Recipient 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Known hypersensitivity thalidomide Lenalidomide . 5 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 6 . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine prior infection immune ( i.e. , carrier ) eligible . Donor The following category donor acceptable : 1 . HLAmatched related donor ( 5/6 6/6 match ) : Minimal type necessary serologic type class I ( A , B ) molecular type class II ( DRB1 ) . 2 . HLAmatched Unrelated Donor ( MUD ) : Molecular identity least HLA A , B , C , DRB1 DQB1 ( 8/10 match ) high resolution typing require . 3 . Syngeneic donor eligible . 4 . The donor must healthy must acceptable donor per institutional standard marrow stem cell donation . 5 . Age ≥ 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>